The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...
Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy ...
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.
Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...
FDA approves Mesoblast's Ryoncil, the first U.S. MSC therapy, for children with steroid-refractory acute graft-versus-host disease. In a Phase 3 trial, 70% of SR-aGvHD patients responded to ...
Silviu and the team at Mesoblast have opened a new chapter in harnessing MSC therapies to treat devastating conditions like SR-aGVHD. This approval validates the immense therapeutic promise of MSCs ...
Stockhead on MSN3d
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of tryingAfter years of trying, Mesoblast has won US FDA approval for its stem-cell therapies to treat the fatal graft-versus-host ...
HCT, the addition of itacitinib to standard GvHD prophylaxis is well tolerated and results in low rates of CRS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback